Novanta Inc

Análisis de la acción Novanta Inc (NOVT)

$139.940

+4.492 (+3.21%)Al cierre

Loading chart…
Máximo
141.190
Apertura
137.730
Precio medio ponderado por volumen
139.52
Volumen
409.15K
Capitalización
—
Mínimo
137.430
Importe
57.08M
EV/EBITDA, TTM
22.07

Novanta Inc. is a supplier of core technology solutions, which offer medical and advanced industrial original equipment manufacturers. Its segment includes Automation Enabling Technologies and Medical Solutions. The Automation Enabling Technologies segment designs, manufactures and markets laser beam delivery components, laser beam delivery solutions, CO2 lasers, solid state lasers, ultrafast lasers, optical and inductive encoders, precision motors, integrated stepper motors, servo drives, motion control solutions, intelligent robotic end-of-arm technology solutions, and air bearing spindles to customers worldwide. The Medical Solutions segment designs, manufactures and markets a range of medical grade technologies, including medical insufflators and endoscopic pumps and related disposables, laser beam delivery solutions, video processing and streaming and capture, machine vision technologies, radio frequency identification (RFID) technologies, thermal chart recorders, and others.

www.novanta.com

Análisis de IA of Novanta Inc (NOVT)

Vender

Currently, Novanta Inc. (NOVT) is not a good buy. The stock is trading at $128.79, significantly below its analyst price target of $194, but recent performance shows a concerning RSI of 24.523, indicating oversold conditions. Additionally, insider selling has increased by 134.30% over the last month, which raises red flags about management's confidence in the company's near-term prospects. The stock has also seen a 5-day change of -8.84%, suggesting negative momentum. The main risk is the high P/E ratio of 82.54, indicating that the stock may be overvalued compared to its earnings potential.

Recomendaciones de analistas (1)

Comprar
1 Comprar
0 Mantener
0 Vender
Actual: 139.94
Mínimo
—
Promedio
—
Máximo
—

Baird

2026-08-07

Precio objetivo

$194

Superar al mercado

Baird

2026-05-13

Precio objetivo

$173

Superar al mercado

Baird

2026-03-30

Precio objetivo

$144

Superar al mercado

Baird

2026-02-25

Precio objetivo

$150

Neutral

Baird

2025-08-11

Precio objetivo

$133

Neutral

Métricas de valoración

El PER previsto actual de Novanta Inc (NOVT) es 8.39, frente a su media de 5 años de 39.35.

PER previsto

Muy infravalorado
Media 5A P/E
39.35
P/E actual
8.39
Sobrevalorada
54.39
Infravalorada
24.31

EV/EBITDA previsto

Infravalorado
Media 5A EV/EBITDA
26.87
EV/EBITDA actual
22.07
Sobrevalorada
31.25
Infravalorada
22.49

Precio/ventas previsto

Infravalorado
Media 5A P/S
5.43
P/S actual
3.90
Sobrevalorada
6.39
Infravalorada
4.47

Escenarios de precio de Alphio AI para NOVT

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%NOVT

$155.23

Precio del escenario

B

Base

Base · 50%NOVT

$145.52

Precio del escenario

B

Bajista

Bajista · 25%NOVT

$116.12

Precio del escenario

Ballenas con NOVT en cartera

B

Baron Capital Group, Inc.

+ Con en carteraNOVT

+15.09%

Rentabilidad a 3 meses

C

CastleArk Management LLC

+ Con en carteraNOVT

+8.92%

Rentabilidad a 3 meses

C

Champlain Investment Partners, LLC

+ Con en carteraNOVT

+6.34%

Rentabilidad a 3 meses

O

Osterweis Capital Management, Inc.

+ Con en carteraNOVT

+5.51%

Rentabilidad a 3 meses

S

Southpoint Capital Advisors LP

+ Con en carteraNOVT

+5.19%

Rentabilidad a 3 meses

F

Fenimore Asset Management, Inc.

+ Con en carteraNOVT

+1.73%

Rentabilidad a 3 meses

Cronología de eventos

2026-08-05 (ET)

17:00:00

Novanta Reports Q2 Revenue of $265.8 Million

17:00:00

Sees Q3 Revenue of $300M-$304M

17:00:00

Sees FY26 Revenue of $1.13B-$1.14B

2026-07-27 (ET)

08:30:00

Novanta Completes Acquisition of Riverpoint Medical

2026-06-29 (ET)

17:30:00

Selling Stockholders Plan to Sell 2.14M Common Shares

Noticias

Preguntas frecuentes sobre NOVT, respondidas por Alphio AI

Novanta Inc. is a supplier of core technology solutions, which offer medical and advanced industrial original equipment manufacturers. Its segment includes Automation Enabling Technologies and Medical Solutions. The Automation Enabling Technologies segment designs, manufactures and markets laser beam delivery components, laser beam delivery solutions, CO2 lasers, solid state lasers, ultrafast lasers, optical and inductive encoders, precision motors, integrated stepper motors, servo drives, motion control solutions, intelligent robotic end-of-arm technology solutions, and air bearing spindles to customers worldwide. The Medical Solutions segment designs, manufactures and markets a range of medical grade technologies, including medical insufflators and endoscopic pumps and related disposables, laser beam delivery solutions, video processing and streaming and capture, machine vision technologies, radio frequency identification (RFID) technologies, thermal chart recorders, and others. It operates in the Technology sector (MISCELLANEOUS ELECTRICAL MACHINERY, EQUIPMENT & SU industry).

Currently, Novanta Inc. (NOVT) is not a good buy. The stock is trading at $128.79, significantly below its analyst price target of $194, but recent performance shows a concerning RSI of 24.523, indicating oversold conditions. Additionally, insider selling has increased by 134.30% over the last month, which raises red flags about management's confidence in the company's near-term prospects. The stock has also seen a 5-day change of -8.84%, suggesting negative momentum. The main risk is the high P/E ratio of 82.54, indicating that the stock may be overvalued compared to its earnings potential.

1 analysts cover NOVT: 1 rate it Buy, 0 Hold and 0 Sell.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar